Skip to content

Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction

A Prospective, Multicenter, Open-label, Single-arm Clinical Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) IOL for Correction of Aphakia Following Cataract Extraction

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07650201
Enrollment
340
Registered
2026-06-16
Start date
2026-08-01
Completion date
2028-11-01
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphakia, Postcataract

Brief summary

A study to learn how well an artificial lens, called an intraocular lens (IOL), works in adults who have cataract surgery. During this type of surgery, the eye's natural lens is removed and replaced with an artificial lens to help restore vision. The main goal of the study is to evaluate vision after the lens is placed in the eye. About one year after surgery, participants' vision will be measured to understand how clearly they can see. The study will also look at how the lens performs over time, including how well it remains in place in the eye. The results of this study will help provide more information about how this lens performs in adults undergoing cataract surgery.

Interventions

DEVICEKI-362-US1 (YP2.2VM)

Injector and one-piece (1P) monofocal IOL

Sponsors

Kowa Research Institute, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Are able and willing to provide written informed consent, attend all scheduled visits, and comply with all trial procedures and follow-up * Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated * Meet all other inclusion criteria outlined in the clinical study protocol

Exclusion criteria

* Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome * Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk * Meet any other

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Participants whose BCDVA Achieved 0.30 logMAR or Better at Form 5Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390A binary outcome of achieving best-corrected distance visual acuity (BCDVA) of 0.30 logarithm of the minimum angle of resolution (logMAR) or better, or not, at postoperative days 330-390 (Form 5) BCDVA will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts
Proportion of Participants with Incidence of Selected Ocular Adverse EventsBaseline through end of study (up to 15 months)This safety outcome measure evaluates whether participants experience any of the following ocular adverse events after treatment, recorded as a binary outcome (occurrence: yes/no). Cumulative adverse events assessed include Cystoid macular edema, Hypopyon, Endophthalmitis, lens dislocation from the posterior chamber, Pupillary block, Retinal detachment, and secondary surgical interventions (excluding posterior capsulotomies). In addition, persistent adverse events are assessed as present or absent, including corneal stroma edema, persistent Cystoid macular edema, Iritis, and elevated intraocular pressure requiring treatment.

Secondary

MeasureTime frameDescription
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 4Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time. Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 4) remains within predefined thresholds.
Proportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 5Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time. Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 4Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time. Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit 4 (Form 4) remains within predefined thresholds.
Proportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 5Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390Evaluation of the rotational stability of the implanted monofocal IOL by assessing changes in lens axis alignment over time. Stability is determined using binary outcomes (yes/no) based on whether the absolute difference in lens position between baseline (Form 0) and follow-up visit (Form 5) remains within predefined thresholds.

Contacts

CONTACTDirector, Clinical Operations
Clinical@KowaUS.com919-433-1600
STUDY_CHAIRShona Pendse, MD, MMSc

Kowa Research Institute, Inc.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026